A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARgamma-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARgamma-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Therapeutic Use
  • Sponsors Clementia Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 14 Oct 2016 According to a Clementia Pharmaceuticals media release, the company expects to publish full results of this phase 2 trial in 2017.
    • 14 Oct 2016 Results published in the Clementia Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top